Clinical trial · Interventional
Real-time Motion Management During Prostate and Lung Radiotherapy
NCT05844761CI-TRIAL-00119546REMINDactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this interventional non-inferiority trial is to assess the accuracy of different real-time motion management radiotherapy techniques. The main question the study aims to answer are: * What are the target margins for radiotherapy with motion management that are not inferior to target margin without motion management * What are the dosimetric and geometrical accuracy to patient for the motion management techniques. Participants will answer QoL questionary, and the accuracy of treatment will be assessed from treatment data.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Cancer of Prostate | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Lung Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Synchrony MLC tracking and lung adaptive model with margin reduction | Radiation | — | UNRESOLVED |
| Synchrony MLC tracking on fiducials with margin reduction | Radiation | — | UNRESOLVED |
| Triggered imaging on TrueBeam with margin reduction | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Triggered Imaging with TrueBeam for prostate cancer
- description
- Patients will undergo radiotherapy using the Triggered Imaging technique with TrueBeam for prostate cancer. The technology on the TrueBeam allows for monitoring and gating of the radiation beam in relation to the target position.
- interventionNames
- Radiation: Triggered imaging on TrueBeam with margin reduction
- type
- EXPERIMENTAL
- label
- Synchrony with Radixact for prostate cancer
- description
- Patients will undergo radiotherapy using the Synchrony technique with Radixact for prostate cancer. Multi-Leaf Collimator Adaptation (MLC) and kilovoltage (kV) Intrafraction Monitoring with the Synchrony technique on the Radixact radiotherapy machine.
- interventionNames
- Radiation: Synchrony MLC tracking on fiducials with margin reduction
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For prostate cancer patients: * Patients histologically proven prostate adenocarcinoma * Prostate specific antigen (PSA) obtained within three months prior to enrollment * Localised prostate cancer at any stage eligible for radiotherapy: i.e. any T- or Gleason stage, but no pelvic lymph nodes can be included within the target to be treated * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to understand and the willingness to sign a written informed consent document. * Hypofractionated radiation therapy (HYPO) fractionated patients with a prescribed dose of 42.7Gy in 7 fractions. * MRIOnly workflow meaning synthetic generated CT based on Magnetic resonance imaging (MRI) * Patients over 40 years old For lung cancer patients: * Lung cancer or localised metastatic disease from other cancer diagnoses, accepted for stereotactic radiotherapy to 45Gy in 3 fractions * Lesion distinguishable on Computer Tomography and where the majority of adjacent tissue is the lung. * Ability to understand and the willingness to sign a written informed consent document. * Is able to perform treatment simulation Exclusion Criteria: For prostate cancer patients: * Patient must have three gold fiducial markers inserted in the prostate * Patients with artificial Hip(s), lumbar spinal surgical rods or other large metallic pelvic implants * Patients with overlapping implanted gold fiducials in X-ray imaging * Unfeasible to track fiducials with kv imaging/existing online imaging systems For lung cancer patients: * Previous treatment with radiotherapy for lung cancer or lung metastasis * Idiopathic lung fibrosis
References
Publications (0)
Data not yet available
No reference posted for this study.